Palatin Technologies, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.51) Per Share (NYSEAMERICAN:PTN)

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Palatin Technologies in a report issued on Tuesday, October 1st. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will post earnings per share of ($0.51) for the quarter. HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. HC Wainwright also issued estimates for Palatin Technologies’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($2.03) EPS.

Palatin Technologies (NYSEAMERICAN:PTN) last posted its earnings results on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share for the quarter.

Palatin Technologies Price Performance

NYSEAMERICAN:PTN opened at $0.88 on Thursday. The firm has a market capitalization of $17.11 million, a price-to-earnings ratio of -0.36 and a beta of 1.01. Palatin Technologies has a 52 week low of $0.68 and a 52 week high of $5.65.

Institutional Investors Weigh In On Palatin Technologies

An institutional investor recently bought a new position in Palatin Technologies stock. XTX Topco Ltd bought a new stake in Palatin Technologies, Inc. (NYSEAMERICAN:PTN) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,631 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. XTX Topco Ltd owned about 0.08% of Palatin Technologies as of its most recent filing with the Securities & Exchange Commission. 11.50% of the stock is owned by hedge funds and other institutional investors.

Palatin Technologies Company Profile

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.